On 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Medivir licenses HCV drug MIV-802 to Chinese Ascletis
Latest NewsMedivir AB has exclusively licenced Greater China development and commercialisation rights of its preclinical candidate drug MIV-802 to Chinese drug developer Ascletis Bioscience Co. Ltd.
Checkpoint modulation: Blocking the tumours immune evasion strategies
BackgroundBelgian, Swiss, and US researchers have found a new way to boost efficacy in cancer immunotherapy. In mid-April, they reported that cancer cells actively block tumour infiltration of cytotoxic T cells, but that this process can be reversed using angiogenesis blockers. Some Big pharma companies have already jumped on the bandwagon of angiogenesis/PDL1 combination therapy.
Swedish reasearchers link up cancer survival to protein levels
Latest NewsUsing a national supercomputer, Swedish researchers have analysed how protein expression of the 315 known cancer genes translates into cancer overall survival.
Metsä Group started up its bioproduct mill
Latest NewsFinnish Metsä Group has started its mill for bio-based products. The €1.2bn investments production capacity is 1.3 million tonnes of softwood pulp a year.
Oxford Immunotec value drops after public offering
Latest NewsUK-headquartered immunodiagnostics specialist Oxford Immunotec Global plc’s share value slipped by $1.31 to $16.02 after the company raised US-$40.125m on Monday in an public offering of 2.5 million ordinary shares at Nasdaq underwritten by BTIG LLC.
Cleaning up the oceans
BackgroundFrench green chemistry pioneer, Carbios SA (Clermont-Ferrand) announced in March that it has secured equity financing of €2.5m from Kepler Cheuvreux through the acquisition of 380,000 shares over 24 months.
Mundipharma pays US$250 for CAP7.1
Latest NewsGerman CellAct GmbH has cashed in US$250m (€212m) from Mundipharma in a licence deal for CAP7.1, a Phase II drug to treat the rare biliary tract cancer.
Orchard Therapeutics appoints Mark Rothera as CEO
AppointmentsGene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
IP: Brexit and patents
OpinionOn 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Sepsis: Adrenomed receives approval for POC study in patients with early septic shock
Latest NewsGermany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 study, 300 patients will be enrolled in Germany, Belgium, France and the Netherlands for proof of safety and efficacy.